Stock Ratings / Health Care / SCLX / earnings

JSPR (41) PLUR (39) DYAI (33) BCDA (49) ⌘ Pro Terminal →

Scilex Holding Company (SCLX) Next Earnings Date & Expected ±12.5% Move

Q: When is SCLX's next earnings date?

Based on SEC filing cadence, Scilex Holding Company (SCLX)'s next quarterly reporting window is estimated around Dec 30, 2026.

Q: How much is SCLX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for SCLX, spanning a range between $1.8 and $2.32.

$2.06 -1.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Scilex Holding Company (SCLX) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $17.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SCLX)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.26 Expected Swing

MODEL EARNINGS SETUP GAUGE

SCLX Quantitative Pre-Earnings Setup: 52/100

Trailing EPS: $4.25 • YoY Revenue Growth: -46.5%

Model Bullish Setup (52/100)Model Risk Weight (48/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$30.3M	-$374.1M	$3.7M	98%
FY 2024	2024-12-31	$56.6M	-$72.8M	$19.3M	98%
FY 2023	2023-12-31	$46.7M	-$114.3M	-$20.7M	92%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCLX)

✓Walkthrough of SCLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SCLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -68.55%▼ SUPPORT BREAKDOWN

2026-10-30O $2.05H $2.06L $1.83C $2.06VOL 49.6K

RES: $6.85SUP: $3.26SMA50: $4.17SMA200: $5.31

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SCLX Butterfly Map → + Track SCLX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -46.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SCLX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SCLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SCLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCLX)

Health Care Rank #327 of 1016 ⚔️ JSPR vs SCLX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SCLX vs. JSPR, PLUR, DYAI, BCDA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Scilex Holding Company (SCLX) ranks #327 by composite RQD confidence (52/100, grade D+) and #842 by equity capitalization ($17.5M). Within this direct 5-issuer industry benchmark cohort, SCLX leads on earnings valuation at N/A trailing P/E, while SCLX leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. SCLX currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SCLX ACTIVE Scilex Holding Company	D+	52/100	—	96.0%	-35.0%	-1.43%	$17.5M	Benchmark Subject
JSPR Jasper Therapeutics Inc.	D-	41/100	—	—	-35.0%	-1.26%	$17.7M	/jspr-vs-sclx →
PLUR Pluri Inc.	D-	39/100	—	49.0%	-35.0%	-2.44%	$16.1M	/plur-vs-sclx →
DYAI Dyadic International Inc.	E	33/100	—	24.9%	-35.0%	-8.40%	$14.5M	/dyai-vs-sclx →
BCDA BioCardia Inc.	D	49/100	—	—	-35.0%	-2.26%	$14.0M	/bcda-vs-sclx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001820190

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scilex Holding Company (SCLX) reported GAAP revenue of $30.3M (-46.5% vs. FY2024 revenue of $56.6M , and -35.3% cumulative change since FY2023) , GAAP net income of -$374.1M, operating cash flow of $3.8M, and free cash flow of $3.7M (-81.0% YoY). On the balance sheet, SCLX closed FY2025 with $365.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$30.3M	-$374.1M	$3.8M	$3.7M	$365.0M	—
FY2024 (FY)	2024-12-31	$56.6M	-$72.8M	$19.3M	$19.3M	$93.0M	—
FY2023 (FY)	2023-12-31	$46.7M	-$114.3M	-$20.7M	-$20.7M	—	—

3. SCLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Scilex Holding Company (NASDAQ: SCLX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $2.06 (-1.43% 1D, market cap $17.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCLX ranks #327 in composite RQD confidence.

How does SCLX compare to JSPR and PLUR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, JSPR (Jasper Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $17.7M) and PLUR (Pluri Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCLX?

Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCLX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCLX last traded at $2.06 (-1.43% on volume of 7,406 shares), positioning the stock -50.60% below its 50-day simple moving average ($4.17) and -61.21% below its 200-day simple moving average ($5.31). Across its 52-week range of $1.83 to $16.81, SCLX sits at the 1.5% percentile with a 14-day RSI of 14.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.80 to $2.32).

SCLX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is SCLX's next earnings date?

Based on SEC filing cadence, Scilex Holding Company (SCLX)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is SCLX stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for SCLX, spanning a range between $1.8 and $2.32.

Direct Sub-Reports: SCLX RQD Cockpit SCLX 12M Forecast SCLX Earnings & Move SCLX Dividends & DRIP SCLX Insiders & 13F SCLX Whale Options SCLX Profit Sankey SCLX News & Why